Mucolytic therapy for respiratory diseases in children and the use of ambroxol


DOI: https://dx.doi.org/10.18565/pharmateca.2019.10.92-96

G.A. Samsygina

Feron LLC, Moscow, Russia

Cough is one of the most frequent manifestations of respiratory diseases, especially in children, and it is often caused by inflammation of the tracheobronchial tree; the mucociliary transport system plays the main role in the protection of tracheobronchial tree and maintains airway patency. Disorders of the production and rheological properties of airway secretion contribute to cough, causing mucociliary transport (mucociliary clearance – MCC) disorders. In slowing the MCC, an important role is played by hyperplasia of the bronchial mucosa under the influence of infectious, allergic or other inflammation, edema of the mucous membrane of the tracheobronchial tree, increased secretion of mucus, increased viscosity of bronchial secretion, etc. Among mucolytic drugs used to treat bronchopulmonary diseases in children accompanied by cough, Ambroxol deserves attention. The mechanism of its action is determined by a pronounced expectorant, secretolytic and secretomotor action on the bronchopulmonary system, anti-inflammatory and slight antioxidant effects, as well as stimulation of production and blocking the destruction of surfactant.


For citations: Samsygina G.A. Mucolytic therapy for respiratory diseases in children and the use of ambroxol. Farmateka. 2019;26(10):92–96. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.10.92-96 


About the Autors


Corresponding author: Galina A. Samsygina, MD, Professor, Deputy Editor-in-Chief of the «Pediatria» journal n.a. G.N. Speransky, Employee of Feron LLC, Moscow, Russia; e-mail: gsamsygina@mail.ru; ORCID: https://orcid.org/0000-0002-2982-5933 
Address: 37, Leningradsky Prospekt, Moscow 125167, Russian Federation


Similar Articles


Бионика Медиа